{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:12:08Z","timestamp":1787580728922,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.isci.2020.101969","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T09:17:17Z","timestamp":1610270237000},"page":"101969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-9948","authenticated-orcid":false,"given":"Sooyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-3379","authenticated-orcid":false,"given":"Ashish","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-0002","authenticated-orcid":false,"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6165-664X","authenticated-orcid":false,"given":"Takeshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-7436","authenticated-orcid":false,"suffix":"Jr.","given":"Michael","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2020.101969_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3748\/wjg.v13.i1.48","article-title":"Hepatitis B virus replication","volume":"13","author":"Beck","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.isci.2020.101969_bib2","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1128\/JVI.06867-11","article-title":"Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses","volume":"86","author":"Bedard","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.isci.2020.101969_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2020.101969_bib5","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus-specific T\u00a0cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)ide analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2020.101969_bib6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hep.21187","article-title":"Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication","volume":"43","author":"Bonvin","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2020.101969_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.antiviral.2012.10.001","article-title":"The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy","volume":"96","author":"Chang","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.isci.2020.101969_bib8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.bbrc.2014.07.023","article-title":"Inhibition of Hepatitis B virus replication by SAMHD1","volume":"450","author":"Chen","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.isci.2020.101969_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1146\/annurev-immunol-042617-053309","article-title":"RIG-I and other RNA sensors in antiviral immunity","volume":"36","author":"Chow","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.isci.2020.101969_bib10","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.1128\/JVI.01481-15","article-title":"Alteration of mature nucleocapsid and enhancement of covalently closed circular DNA formation by hepatitis B virus core mutants defective in complete-virion formation","volume":"89","author":"Cui","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib11","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ijc.31874","article-title":"Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells","volume":"144","author":"Dassler-Plenker","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2020.101969_bib12","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1002\/hep.22920","article-title":"Benefits and risks of nucleoside analog therapy for hepatitis B","volume":"49","author":"Dienstag","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2020.101969_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41573-019-0057-9","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"19","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2020.101969_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/jir.2010.0101","article-title":"The ISG56\/IFIT1 gene family","volume":"31","author":"Fensterl","year":"2011","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.isci.2020.101969_bib15","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/JVI.02744-14","article-title":"Interferon-induced Ifit proteins: their role in viral pathogenesis","volume":"89","author":"Fensterl","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature07710","article-title":"AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA","volume":"458","author":"Fernandes-Alnemri","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.isci.2020.101969_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2020.101969_bib18","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation","volume":"81","author":"Guo","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2018.11.006","article-title":"5'-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice","volume":"161","author":"Han","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.isci.2020.101969_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0022-2836(67)90307-5","article-title":"Selective extraction of polyoma DNA from infected mouse cell cultures","volume":"26","author":"Hirt","year":"1967","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.isci.2020.101969_bib21","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.4049\/jimmunol.1501958","article-title":"Cutting edge: the RIG-I ligand 3pRNA potently improves CTL cross-priming and facilitates antiviral vaccination","volume":"196","author":"Hochheiser","year":"2016","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.isci.2020.101969_bib22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nm.3253","article-title":"Regulation of hepatic innate immunity by hepatitis C virus","volume":"19","author":"Horner","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2020.101969_bib23","article-title":"Rapid turnover of HBV cccDNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients","author":"Huang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2020.101969_bib24","series-title":"Anti-viral Compounds, Pharmaceutical Compositions, and Methods of Use Thereof","first-page":"23","author":"Iadonato","year":"2018"},{"key":"10.1016\/j.isci.2020.101969_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2016.03.008","article-title":"Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus","volume":"130","author":"Isorce","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.isci.2020.101969_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2020.101969_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.12998\/wjcc.v6.i13.589","article-title":"Update on global epidemiology of viral hepatitis and preventive strategies","volume":"6","author":"Jefferies","year":"2018","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.isci.2020.101969_bib28","doi-asserted-by":"crossref","first-page":"11056","DOI":"10.1128\/JVI.01964-15","article-title":"Pathogen-associated molecular pattern recognition of hepatitis C virus transmitted\/founder variants by RIG-I is dependent on U-core length","volume":"89","author":"Kell","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.isci.2020.101969_bib30","doi-asserted-by":"crossref","first-page":"28123","DOI":"10.1074\/jbc.M300064200","article-title":"Central role of a serine phosphorylation site within duck hepatitis B virus core protein for capsid trafficking and genome release","volume":"278","author":"Kock","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.isci.2020.101969_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2020.101969_bib32","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2020.101969_bib33","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1128\/JVI.02395-06","article-title":"Inhibition of hepatitis B virus polymerase by entecavir","volume":"81","author":"Langley","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1089\/jir.2019.0015","article-title":"Endogenous nucleic acid recognition by RIG-I-like receptors and cGAS","volume":"39","author":"Lee","year":"2019","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.isci.2020.101969_bib35","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28025","article-title":"Present and future therapies of hepatitis B: from discovery to cure","volume":"62","author":"Liang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2020.101969_bib36","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.isci.2020.101969_bib37","doi-asserted-by":"crossref","first-page":"e1006784","DOI":"10.1371\/journal.ppat.1006784","article-title":"The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation","volume":"13","author":"Long","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2020.101969_bib38","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.isci.2020.101969_bib39","doi-asserted-by":"crossref","first-page":"e03423-19","DOI":"10.1128\/mBio.03423-19","article-title":"Involvement of host ATR-CHK1 pathway in hepatitis B virus covalently closed circular DNA formation","volume":"11","author":"Luo","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.isci.2020.101969_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1128\/MMBR.05012-11","article-title":"Emerging role of ubiquitination in antiviral RIG-I signaling","volume":"76","author":"Maelfait","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.isci.2020.101969_bib41","first-page":"99","article-title":"Hepadna viruses: hepatitis B and related viruses","volume":"105","author":"Marion","year":"1983","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.isci.2020.101969_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jhep.2004.09.017","article-title":"Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure","volume":"42","author":"Maynard","year":"2005","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.isci.2020.101969_bib43","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","article-title":"High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study","volume":"50","author":"Moucari","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.isci.2020.101969_bib44","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1053\/j.gastro.2018.01.044","article-title":"HBV bypasses the innate immune response and does not protect HCV from antiviral activity of interferon","volume":"154","author":"Mutz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2020.101969_bib45","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.isci.2020.101969_bib46","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/jvi.69.6.3350-3357.1995","article-title":"The covalently closed duplex form of the hepadnavirus genome exists in\u00a0situ as a heterogeneous population of viral minichromosomes","volume":"69","author":"Newbold","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib47","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2020.101969_bib48","doi-asserted-by":"crossref","first-page":"a016246","DOI":"10.1101\/cshperspect.a016246","article-title":"Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors","volume":"7","author":"Pandey","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.isci.2020.101969_bib49","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/JVI.02202-15","article-title":"Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR pathway","volume":"90","author":"Pattabhi","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib50","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B","volume":"49","author":"Perrillo","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2020.101969_bib51","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fimmu.2017.00621","article-title":"Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients","volume":"8","author":"Phillips","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2020.101969_bib52","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.vaccine.2017.01.053","article-title":"A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response","volume":"35","author":"Probst","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2020.101969_bib53","doi-asserted-by":"crossref","first-page":"e1005893","DOI":"10.1371\/journal.ppat.1005893","article-title":"DNA polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus","volume":"12","author":"Qi","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2020.101969_bib54","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1073\/pnas.1730940100","article-title":"Nuclear import of hepatitis B virus capsids and release of the viral genome","volume":"100","author":"Rabe","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.isci.2020.101969_bib55","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","article-title":"Lambda interferon inhibits hepatitis B and C virus replication","volume":"79","author":"Robek","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature07106","article-title":"Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA","volume":"454","author":"Saito","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.isci.2020.101969_bib57","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.cellsig.2005.08.006","article-title":"IKK-i signals through IRF3 and NFkappaB to mediate the production of inflammatory cytokines","volume":"18","author":"Sankar","year":"2006","journal-title":"Cell. Signal."},{"key":"10.1016\/j.isci.2020.101969_bib58","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.ppat.1002839","article-title":"Uridine composition of the poly-U\/UC tract of HCV RNA defines non-self recognition by RIG-I","volume":"8","author":"Schnell","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2020.101969_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.isci.2020.101969_bib60","doi-asserted-by":"crossref","first-page":"e02230-18","DOI":"10.1128\/JVI.02230-18","article-title":"Cellular DNA topoisomerases are required for the synthesis of hepatitis B virus covalently closed circular DNA","volume":"93","author":"Sheraz","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib61","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1128\/JVI.00535-12","article-title":"Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes","volume":"86","author":"Shi","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib62","doi-asserted-by":"crossref","first-page":"e1007742","DOI":"10.1371\/journal.ppat.1007742","article-title":"DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA","volume":"15","author":"Tang","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2020.101969_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17460441.2017.1255195","article-title":"The current status and future directions of hepatitis B antiviral drug discovery","volume":"12","author":"Tang","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.isci.2020.101969_bib64","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1126\/science.1092066","article-title":"Inhibition of hepatitis B virus replication by APOBEC3G","volume":"303","author":"Turelli","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.isci.2020.101969_bib65","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.isci.2020.101969_bib66","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/ni.1932","article-title":"IFI16 is an innate immune sensor for intracellular DNA","volume":"11","author":"Unterholzner","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2020.101969_bib67","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1128\/jvi.67.11.6507-6512.1993","article-title":"Novel mechanism for reverse transcription in hepatitis B viruses","volume":"67","author":"Wang","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.isci.2020.101969_bib68","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2020.101969_bib69","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2020.101969_bib70","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.isci.2020.101969_bib71","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3851\/IMP3239","article-title":"RIG-I enhances interferon-alpha response by promoting antiviral protein expression in patients with chronic hepatitis B","volume":"23","author":"Wu","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.isci.2020.101969_bib72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0042-6822(90)90206-7","article-title":"In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway","volume":"175","author":"Wu","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.isci.2020.101969_bib73","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2020.101969_bib74","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-gamma and tumor necrosis factor-alpha produced by T\u00a0cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2020.101969_bib75","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41423-018-0006-2","article-title":"Type III interferon-induced CBF\u03b2 inhibits HBV replication by hijacking HBx","volume":"16","author":"Xu","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.isci.2020.101969_bib76","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.isci.2020.101969_bib77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.21986","article-title":"CXCL10 regulates liver innate immune response against ischemia and reperfusion injury","volume":"47","author":"Zhai","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2020.101969_bib78","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/eji.201746959","article-title":"Post-translational regulation of antiviral innate signaling","volume":"47","author":"Zhou","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2020.101969_bib79","doi-asserted-by":"crossref","first-page":"a021501","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.isci.2020.101969_bib80","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004220311664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004220311664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:27:23Z","timestamp":1762878443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004220311664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2589004220311664"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2020.101969","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2020.101969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101969"}}